Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0376358 (
prostate cancer
)
59,338
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The actin-like protein of the SWI/SNF complex,
BAF53A
, regulates gene expression by the gene-specific chromatin remodeling of target genes. However, the function of
BAF53A
in the androgen receptor pathway in
prostate cancer
cells remains unclear. Here, we demonstrated that
BAF53A
positively regulates the expression of endogenous AR target genes (e.g. PSA, TMPRSS2, FKBP5, and KLK2) in LNCaP cells. It functions as a coactivator in AR-mediated transcription by interacting with other nuclear receptor coactivators, such as p300 and FLII, and is associated with AR in the presence of dihydrotestosterone (DHT). The DHT-induced recruitment of
BAF53A
to the proximal and distal androgen response elements (AREs) of the PSA gene in the presence of BRG1 (but not BRM) was inhibited by an AR antagonist, suggesting the coactivator function of
BAF53A
in the SWI/SNF complex. Depletion of
BAF53A
in LNCaP cells resulted in a significant decrease in growth rate. Furthermore, the expression of
BAF53A
in
prostate cancer
tissue was significantly elevated, compared to that in normal prostate tissue, and correlated with the expression of AR, and BRG1, but not BRM. Therefore, our results suggested that
BAF53A
plays an important role in the expression of AR target genes in
prostate cancer
, and can be used clinically for the treatment of
prostate cancer
.
...
PMID:BAF53A regulates androgen receptor-mediated gene expression and proliferation in LNCaP cells. 3027 85
